potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus)

There's now concern about a potential cancer risk for Protopic (tacrolimus) and Elidel (pimecrolimus).

FDA is adding a black box warning to these topical immunosuppressants used for eczema. Patients will soon get a Medication Guide when their prescriptions are filled.

It's NOT known for sure if these drugs increase cancer risk.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote